跳至主要内容
临床试验/NCT00124540
NCT00124540已完成不适用

Misoprostol for Preventing Postpartum Hemorrhage

Gynuity Health Projects5 个研究点 分布在 3 个国家目标入组 1,200 人开始时间: 2005年8月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
1,200
试验地点
5
主要终点
Blood loss =>500 mls within one hour after enrollment

研究概览

简要总结

This hospital-based, multicenter, randomized, placebo-controlled trial will assess the effects of misoprostol as part of active management of the third stage of labor on postpartum blood loss, complications, and side effects. Twelve hundred eligible women will receive routine oxytocics (oxytocin 5-10 IU) plus either 400 mcg sublingual misoprostol or placebo during or immediately after delivery. The primary outcome will be measured blood loss of =>500 mls within one hour after enrollment.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Prevention
盲法
Triple (Participant, Care Provider, Investigator)

入排标准

性别
Female
接受健康志愿者

入选标准

  • Women who have given birth to 1 or more live-born infants (para 1 or more)
  • Vaginal delivery

排除标准

  • Refusal or inability to give informed consent
  • Delivery regarded as abortion according to local gestational age limits
  • Inability to take misoprostol sublingually
  • Cesarean section
  • Assisted vaginal delivery

研究组 & 干预措施

1

Placebo Comparator

placebo resembling misoprostol

干预措施: placebo (Drug)

2

Experimental

misoprostol

干预措施: misoprostol (Drug)

结局指标

主要结局

Blood loss =>500 mls within one hour after enrollment

次要结局

  • Blood loss =>1000 mls within one hour after enrollment
  • Mean blood loss after enrollment
  • Blood transfusion
  • Hemoglobin level <8 g/dL 24 hours after delivery
  • Maternal morbidity and mortality
  • Side effects

研究者

发起方
Gynuity Health Projects
申办方类型
Other

研究点 (5)

Loading locations...

相似试验

Misoprostol for Preventing Postpartum Hemorrhage | 临床试验